| Dr Michael Christopher Large, MD | |
|
14300 E 138th Ste A, Fishers, IN 46037-0087 | |
| (317) 813-1660 | |
| (317) 813-1667 |
| Full Name | Dr Michael Christopher Large |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 19 Years |
| Location | 14300 E 138th Ste A, Fishers, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346489630 | NPI | - | NPPES |
| 201191980 | Medicaid | IN | |
| 000000826877 | Other | IN | ANTHEM PIN |
| 1548340177 | Other | IN | NAAB ROAD DME NPI |
| 100194370 | Other | IN | GROUP MEDICAID NUMBER |
| 1487680518 | Other | IN | GROUP NPI |
| 200288740 | Other | IN | GROUP MEDICAID NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 125-049267 (Illinois) | Secondary |
| 208800000X | Urology | 01072896A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Health At Home Llc | Fishers, IN | Home health agency |
| Community Hospital North | Indianapolis, IN | Hospital |
| Community Hospital East | Indianapolis, IN | Hospital |
| Community Hospital Of Anderson And Madison County | Anderson, IN | Hospital |
| Hancock Regional Hospital | Greenfield, IN | Hospital |
| Community Hospital South, Inc. | Indianapolis, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Physicians Of Indiana Inc | 1759416662 | 1319 |
| Urology Of Indiana Llc | 7517870009 | 65 |
News Archive
The blood test could mean that 98% of invasive procedures could be avoided, say the authors. The test uses the latest DNA technology to analyse genetic components in the mother's blood that indicate whether the foetus has Down's.
A single dose of radiotherapy is as "effective" as five doses for end-of-life cancer patients suffering with painful spinal canal compression, finds a large study conducted by UCL.
ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.
By comparing the DNA of 150 pairs of men who share British surnames, researchers have shown that about a quarter of pairs are linked genetically.
Many patients say that the medical information and guidance they can find online is more complete and useful than they receive from their clinicians, according to an editorial in this week's BMJ.
› Verified 5 days ago
| Entity Name | Urology Of Indiana Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487680518 PECOS PAC ID: 7517870009 Enrollment ID: O20031111000154 |
News Archive
The blood test could mean that 98% of invasive procedures could be avoided, say the authors. The test uses the latest DNA technology to analyse genetic components in the mother's blood that indicate whether the foetus has Down's.
A single dose of radiotherapy is as "effective" as five doses for end-of-life cancer patients suffering with painful spinal canal compression, finds a large study conducted by UCL.
ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.
By comparing the DNA of 150 pairs of men who share British surnames, researchers have shown that about a quarter of pairs are linked genetically.
Many patients say that the medical information and guidance they can find online is more complete and useful than they receive from their clinicians, according to an editorial in this week's BMJ.
› Verified 5 days ago
| Entity Name | Community Physicians Of Indiana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619105244 PECOS PAC ID: 1759416662 Enrollment ID: O20100317000717 |
News Archive
The blood test could mean that 98% of invasive procedures could be avoided, say the authors. The test uses the latest DNA technology to analyse genetic components in the mother's blood that indicate whether the foetus has Down's.
A single dose of radiotherapy is as "effective" as five doses for end-of-life cancer patients suffering with painful spinal canal compression, finds a large study conducted by UCL.
ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.
By comparing the DNA of 150 pairs of men who share British surnames, researchers have shown that about a quarter of pairs are linked genetically.
Many patients say that the medical information and guidance they can find online is more complete and useful than they receive from their clinicians, according to an editorial in this week's BMJ.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Christopher Large, MD 679 E County Line Rd, Greenwood, IN 46143-1049 Ph: (317) 885-1250 | Dr Michael Christopher Large, MD 14300 E 138th Ste A, Fishers, IN 46037-0087 Ph: (317) 813-1660 |
News Archive
The blood test could mean that 98% of invasive procedures could be avoided, say the authors. The test uses the latest DNA technology to analyse genetic components in the mother's blood that indicate whether the foetus has Down's.
A single dose of radiotherapy is as "effective" as five doses for end-of-life cancer patients suffering with painful spinal canal compression, finds a large study conducted by UCL.
ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.
By comparing the DNA of 150 pairs of men who share British surnames, researchers have shown that about a quarter of pairs are linked genetically.
Many patients say that the medical information and guidance they can find online is more complete and useful than they receive from their clinicians, according to an editorial in this week's BMJ.
› Verified 5 days ago
Chris A Magee, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 14300 E 138th Ste A, Fishers, IN 46037 Phone: 317-890-2000 Fax: 317-813-1667 | |
Dr. Marcin Zuberek, MD Urology Medicare: Medicare Enrolled Practice Location: 14300 E. 138th St. Bldg. A, Fishers, IN 46037 Phone: 317-890-2000 Fax: 317-813-1667 | |
David M. Scheidler, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 14300 E 138th St., Bldg A, Fishers, IN 46037 Phone: 317-890-2000 Fax: 317-813-1667 | |
Dr. Teresa D Beam, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 14300 E 138th Street, Bldg A, Fishers, IN 46037 Phone: 317-813-1660 Fax: 317-813-1667 | |
Mr. Matthew William Tellman, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 14300 E 138th Bldg A, Fishers, IN 46037 Phone: 317-890-2000 Fax: 317-813-1667 |